AbbVie has announced a voluntary agreement with the Trump administration aimed at lowering drug costs for Americans while ramping up investment in US-based pharmaceutical innovation.

 

Under the deal, AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing. The company will also expand direct-to-patient access through the TrumpRx program for widely used medicines such as ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID.

 

"AbbVie's mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines," said Robert A. Michael, chairman and chief executive officer of AbbVie. 

 

"With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump's call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients."

 

The agreement addresses all four of the administration’s drug pricing priorities, according to AbbVie. In return, the company will receive exemptions from tariffs and future price mandates, while the administration continues efforts to push global markets to better reflect the value of US medical innovation.